- Home
- XLO vs SRZN Comparison
XLO vs SRZN Comparison
Compare XLO & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XLO
- SRZN
- Stock Information
- Founded
- XLO 2016
- SRZN 2015
- Country
- XLO United States
- SRZN United States
- Employees
- XLO N/A
- SRZN 41
- Industry
- XLO Biotechnology: Pharmaceutical Preparations
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- XLO Health Care
- SRZN Health Care
- Exchange
- XLO Nasdaq
- SRZN Nasdaq
- Market Cap
- XLO 37.9M
- SRZN 76.5M
- IPO Year
- XLO 2021
- SRZN N/A
- Fundamental
- Price
- XLO $0.75
- SRZN $9.75
- Analyst Decision
- XLO Buy
- SRZN Strong Buy
- Analyst Count
- XLO 1
- SRZN 2
- Target Price
- XLO $4.00
- SRZN $38.50
- AVG Volume (30 Days)
- XLO 233.4K
- SRZN 18.1K
- Earning Date
- XLO 05-13-2025
- SRZN 05-07-2025
- Dividend Yield
- XLO N/A
- SRZN N/A
- EPS Growth
- XLO N/A
- SRZN N/A
- EPS
- XLO N/A
- SRZN N/A
- Revenue
- XLO $6,344,000.00
- SRZN $10,655,000.00
- Revenue This Year
- XLO $668.96
- SRZN N/A
- Revenue Next Year
- XLO $14.49
- SRZN N/A
- P/E Ratio
- XLO N/A
- SRZN N/A
- Revenue Growth
- XLO N/A
- SRZN N/A
- 52 Week Low
- XLO $0.62
- SRZN $6.00
- 52 Week High
- XLO $1.70
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- XLO 50.44
- SRZN 43.14
- Support Level
- XLO $0.63
- SRZN $8.84
- Resistance Level
- XLO $0.80
- SRZN $10.40
- Average True Range (ATR)
- XLO 0.06
- SRZN 0.79
- MACD
- XLO 0.01
- SRZN -0.09
- Stochastic Oscillator
- XLO 72.93
- SRZN 22.26
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).